Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The relationship between genetic prediction of 486 blood metabolites and the risk of COPD: mendelian randomization study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
    • نبذة مختصرة :
      Metabolic disorders are an important feature of chronic lung disease. Patients diagnosed with chronic obstructive pulmonary disease (COPD) have been found to experience metabolic disorders. Nonetheless, evidence on the causal role of circulating metabolites in promoting or preventing COPD is still lacking. Conducting a methodical examination on the causal connection between blood metabolites and COPD can aid in identifying fresh objectives for the screening and prevention of COPD. Therefore, we performed a two-sample Mendelian randomization (MR) analysis to evaluate the causal association between COPD and 486 blood metabolites.We used two-sample MR techniques and genome-wide association study (GWAS) data to evaluate the correlation between COPD and 486 serum metabolites. To evaluate the causal impact of serum metabolites on the risk of COPD, we predominantly employed inverse variance weighting (IVW) methodology. The MR-Egger regression test was employed to assess multiple validity, while the presence of heterogeneity was examined using the Cochran's Q test. To ensure the reliability of the findings, a leave-one-out analysis was conducted. The Bonferroni correction is used to adjust for multiple comparisons, ensuring rigorous validation of our results.After filtering by IVW and sensitivity analysis, we identified 10 known metabolites including fructose, margarate (17:0), guanosine, 2-stearoylglycerophosphocholine, hexadecanedioate, lactate, 5-oxoproline, paraxanthine, phenyllactate (PLA) and N-acetylglycine. Of these, fructose, margarate (17:0), guanosine, 2-stearoylglycerophosphocholine and hexadecanedioate are risk metabolites, and additionally, lactate, 5-oxoproline, paraxanthine phenyllactate(PLA) and N-acetylglycine are protective metabolites. In addition, the study identified five currently unknown chemical structures. Cochran's Q-test showed no significant heterogeneity, and MR Egger's intercept analysis confirmed the absence of horizontal multidirectionality. Leave-one-out analysis also proved the reliability of the MR analysis.We identified seven COPD-related risks and eight protective human serum metabolites. By combining genomics and metabolism, it provides new insights into the underlying mechanisms of COPD, with important implications for COPD screening and prevention.
      Competing Interests: Declarations. Ethics approval and consent to participate: The data used in this study is publicly available and has been anonymized to ensure that it is not personally identifiable.All participants had obtained local ethical approval and provided informed consent, so no additional ethical approval was required for this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Founding: The establishment of this research was financially supported by the National Project for the Construction of a renowned traditional Chinese medicine experts’ heritage studio (National Chinese Medicine Human Education Letter [2022] No.75), Shandong lung disease heat and poison school inheritance studio construction project (Lu Wei letter [2021] No.45) and the Shandong Province Taishan Scholar Project [grant number tsqn202306392].The study design was independent of the sponsors, as was the collection, analysis, and interpretation of data. The sponsors were not involved in the writing of the report or in the decision to submit the article for publication.
      (© 2025. The Author(s).)
    • References:
      Genet Epidemiol. 2013 Nov;37(7):658-65. (PMID: 24114802)
      Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9. (PMID: 26979502)
      Oxid Med Cell Longev. 2018 Feb 11;2018:5730395. (PMID: 29599897)
      Am J Respir Crit Care Med. 2022 Dec 1;206(11):1317-1325. (PMID: 35914087)
      Prog Retin Eye Res. 2019 Mar;69:57-79. (PMID: 30423446)
      Pharmacol Ther. 2007 Sep;115(3):390-9. (PMID: 17669501)
      Eur Respir J. 2012 Aug;40(2):345-55. (PMID: 22183483)
      Sci Rep. 2019 Jun 27;9(1):9344. (PMID: 31249347)
      Clin Nutr. 2002 Oct;21(5):367-71. (PMID: 12381332)
      Am J Respir Cell Mol Biol. 2019 Aug;61(2):143-149. (PMID: 30874442)
      Lancet Respir Med. 2017 Sep;5(9):747-759. (PMID: 28601554)
      Genet Epidemiol. 2016 May;40(4):304-14. (PMID: 27061298)
      Inflammation. 2017 Jun;40(3):1072-1086. (PMID: 28365872)
      PLoS One. 2015 Dec 16;10(12):e0143937. (PMID: 26674646)
      Biomarkers. 2014 May;19(3):207-13. (PMID: 24649875)
      Front Pharmacol. 2021 Mar 23;12:627503. (PMID: 33833679)
      Sci Rep. 2019 Aug 6;9(1):11367. (PMID: 31388056)
      Genet Epidemiol. 2020 Jun;44(4):313-329. (PMID: 32249995)
      Mol Biosyst. 2012 Oct 30;8(12):3125-33. (PMID: 23051772)
      Genetics. 2023 May 26;224(2):. (PMID: 37019818)
      Eur Respir Rev. 2009 Dec;18(114):213-21. (PMID: 20956146)
      Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S249-S252. (PMID: 30759004)
      Metabolites. 2019 Apr 01;9(4):. (PMID: 30939782)
      PLoS One. 2011 Feb 16;6(2):e16957. (PMID: 21359215)
      Lancet Respir Med. 2017 Dec;5(12):956-967. (PMID: 29146301)
      Am J Respir Crit Care Med. 2015 Oct 1;192(7):785-92. (PMID: 26132989)
      Eur J Clin Nutr. 2022 Jul;76(7):1017-1023. (PMID: 35046567)
      JAMA. 2021 Oct 26;326(16):1614-1621. (PMID: 34698778)
      Front Genet. 2024 Jun 19;15:1424119. (PMID: 38962453)
      Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14. (PMID: 22080510)
      Respir Res. 2024 Apr 18;25(1):171. (PMID: 38637774)
      Stat Methods Med Res. 2012 Jun;21(3):223-42. (PMID: 21216802)
      Bioinformatics. 2019 Nov 1;35(22):4851-4853. (PMID: 31233103)
      Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):902-8. (PMID: 2327654)
      Int J Epidemiol. 2011 Jun;40(3):755-64. (PMID: 21414999)
      Int J Epidemiol. 2015 Apr;44(2):512-25. (PMID: 26050253)
      Am J Clin Nutr. 2000 Jan;71(1 Suppl):393S-6S. (PMID: 10618003)
      ERJ Open Res. 2023 Oct 30;9(5):. (PMID: 37908399)
      Am J Respir Crit Care Med. 2015 Feb 1;191(3):275-84. (PMID: 25494452)
      Int J Mol Sci. 2021 Jul 17;22(14):. (PMID: 34299266)
      Sci Rep. 2021 May 13;11(1):10183. (PMID: 33986393)
      FASEB J. 2023 Dec;37(12):e23316. (PMID: 37983890)
      J Am Soc Nephrol. 2016 Nov;27(11):3253-3265. (PMID: 27486138)
      Am J Respir Crit Care Med. 2001 Sep 15;164(6):1008-11. (PMID: 11587987)
      J Lipid Res. 2006 Mar;47(3):673-6. (PMID: 16371647)
      N Engl J Med. 2017 Oct 26;377(17):1613-1629. (PMID: 28893134)
      Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36. (PMID: 33146552)
      Signal Transduct Target Ther. 2023 Sep 13;8(1):345. (PMID: 37699892)
      Antioxidants (Basel). 2022 Sep 30;11(10):. (PMID: 36290679)
      Front Pharmacol. 2019 Aug 29;10:941. (PMID: 31555131)
      Hum Mol Genet. 2018 Aug 1;27(R2):R195-R208. (PMID: 29771313)
      Am J Respir Crit Care Med. 1998 Sep;158(3):797-801. (PMID: 9731007)
      Food Chem Toxicol. 2021 Dec;158:112579. (PMID: 34597720)
    • Grant Information:
      grant number tsqn202306392 the Shandong Province Taishan Scholar Project; National Chinese Medicine Human Education Letter [2022] No.75 the National Project for the Construction of a renowned traditional Chinese medicine experts' heritage studio; Lu Wei letter [2021] No.45 Shandong lung disease heat and poison school inheritance studio construction project
    • Contributed Indexing:
      Keywords: Blood metabolites; COPD; Mendelian randomization
    • الموضوع:
      Date Created: 20250302 Date Completed: 20250302 Latest Revision: 20250305
    • الموضوع:
      20250305
    • الرقم المعرف:
      PMC11873255
    • الرقم المعرف:
      10.1038/s41598-025-92216-0
    • الرقم المعرف:
      40025290